The University of L'Aquila is a public research university located in L'Aquila, central Italy. It was founded in 1964 and is organized in nine departments. The university presents a scientific-technological character with many research groups.

During the past decade, University of L'Aquila conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 2 clinical trials were completed, i.e. on average, 22.2% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 1 clinical trials were completed. i.e. 12.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of L'Aquila" #1 sponsor was "University of L'Aquila" with 10 trials, followed by "Regeneron Pharmaceuticals" with 2 trials sponsored, "Menarini International Operations Luxembourg SA" with 1 trials sponsored, "National Cancer Institute (NCI)" with 1 trials sponsored and "Yale University" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of L'Aquila" #1 collaborator was "Sanofi" with 2 trials as a collaborator, "Casa Sollievo della Sofferenza IRCCS" with 1 trials as a collaborator, "National Institute of Neurological Disorders and Stroke (NINDS)" with 1 trials as a collaborator, "Novartis" with 1 trials as a collaborator and "Takeda Pharmaceuticals North America, Inc." with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "University of L'Aquila" are "Migraine" (2 trials), "Prostate Cancer" (2 trials), "COVID-19" (1 trials), "Carcinoma, Basal Cell" (1 trials) and "Child, Only" (1 trials). Many other conditions were trialed in "University of L'Aquila" in a lesser frequency.

Most popular intervention types in "University of L'Aquila" are "Drug" (7 trials), "Other" (3 trials), "Device" (1 trials) and "Genetic" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Bicalutamide" (1 trials), "Blood sampling for microRNA testing" (1 trials), "Caregiver" (1 trials) and "Cathodal transcranial direct current stimulation" (1 trials). Other intervention names were less common.

The vast majority of trials in "University of L'Aquila" are 10 trials for "All" genders, 3 trials for "Male" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "University of L'Aquila". undefined are not yet recruiting, 4 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in University of L'Aquila, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in University of L'Aquila, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".